No Data
Assertio Stock Gains Amid Clash With Activist Investor, Q3 Earnings
UBS Upgrades Teva Pharmaceutical Industries(TEVA.US) to Buy Rating, Maintains Target Price $26
Teva to Present at the Jefferies London Healthcare Conference
Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?
UBS Downgrades Teva Pharmaceutical Industries(TEVA.US) to Hold Rating, Maintains Target Price $26
US MOVERS&SHAKERS Nov 04-Nov 08, 2024